Clinical Trials on Non-Small-Cell Lung Carcinoma in United Kingdom

Total 9517 results

National Cancer Institute (NCI)

Completed

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
NRG Oncology
Pennsylvania Department of Health Commonwealth Universal Research Enhancement...

Recruiting

Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Eli Lilly and Company

Completed

A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

Non-Small-Cell Lung Cancer

United Kingdom, Taiwan, Brazil, China, India, Korea, Republic of, Hong Kong
Pathway Genomics

Terminated

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

Lung Neoplasms | Lung Cancer | Adenocarcinoma of the Lung | Cancer of the Lung | Small Cell Carcinoma of the Lung | Non Small Cell Carcinoma of the Lung

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

NSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

United States
Pfizer

Terminated

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Non-small Cell Lung Cancer | Urothelial Cancer

Spain, Czechia, United States, Australia, United Kingdom, Italy, Canada, Hungary
ETOP IBCSG Partners Foundation
Janssen Pharmaceuticals

Recruiting

AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung)

Non Small Cell Lung Cancer

Spain, France, Switzerland, United Kingdom, Singapore, Italy, Netherlands
National Cancer Institute (NCI)

Completed

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States, Mexico, Bolivia, Peru, Venezuela
Fox Chase Cancer Center
National Comprehensive Cancer Network

Recruiting

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

Non-Small Cell Carcinoma of Lung, TNM Stage 4

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer

Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Arcus Biosciences, Inc.
Gilead Sciences

Recruiting

Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer (EDGE-Lung)

Advanced Non-Small Cell Lung Cancer

United States, Korea, Republic of, Australia, United Kingdom, Taiwan, Spain
Indiana University

Completed

Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer

Healthy | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic

United States
Bristol-Myers Squibb

Terminated

Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

Non-small Cell Lung Cancer

Spain, Belgium, France, Italy, Netherlands, Canada, United Kingdom, United States
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Neoplasms | Non-squamous, Non-Small-Cell Lung Cancer

United States, Spain, Korea, Republic of, France, Hong Kong, United Kingdom, Germany, Australia, Taiwan, Poland, Russian Federation, Ukraine
Eli Lilly and Company

Completed

Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Italy, United States, Germany, Poland, Belgium, United Kingdom
National Cancer Institute (NCI)

Recruiting

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Jonathan Riess
National Cancer Institute (NCI)

Not yet recruiting

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Holy Cross Hospital, Florida

Terminated

Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer (HCH003)

Non-Small-Cell Lung Carcinoma

United States
Washington University School of Medicine
Varian Medical Systems

Completed

SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small-Cell-Lung

United States
Washington University School of Medicine
Novartis

Terminated

Pazopanib in Molecularly Selected Patients With Advanced NSCLC

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Rutgers Cancer Institute...

Active, not recruiting

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
Washington University School of Medicine
Varian Medical Systems

Recruiting

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Early Stage Non-small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States, Canada
University of Wisconsin, Madison
AstraZeneca

Terminated

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV

United States
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy

Non-Small Cell Lung Cancer

Italy, Spain, Netherlands, France, Germany, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
Hoffmann-La Roche

Completed

A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Belgium, Spain, United Kingdom, Germany, Italy, Poland, France
University of Nebraska
National Cancer Institute (NCI)

Completed

Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Ohio State University Comprehensive Cancer Center
National Institute on Aging (NIA)

Completed

Resiliency Among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Carcinoma

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Terminated

RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Telik

Completed

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

United States, Australia, Brazil, Chile, Germany, Argentina, Italy, United Kingdom
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer

Small Cell Lung Carcinoma | Non-Small Cell Lung Carcinoma

United States
AstraZeneca

Completed

AZD9291 First Time In Patients Ascending Dose Study (AURA)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

United States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
National Cancer Institute (NCI)

Completed

Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
GlaxoSmithKline

Completed

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase

Lung Cancer, Non-Small Cell

Germany, United Kingdom, Italy, Poland
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
AstraZeneca

Active, not recruiting

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)

Non-Small-Cell Lung Carcinoma

France, Spain, Thailand, Belgium, Korea, Republic of, Netherlands, United States, Brazil, Japan, China, Malaysia, Taiwan, Australia, Denmark
Ohio State University Comprehensive Cancer Center

Completed

Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer

Lung Non-Small Cell Carcinoma | Lung Small Cell Carcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | ALK Gene Mutation | EGFR Gene Mutation | Metastatic Head and Neck... and other conditions

United States
University of Leeds
The Leeds Teaching Hospitals NHS Trust; Iqvia Pty Ltd

Completed

eRAPID: Online Symptom Reporting in Lung Cancer

Thoracic Cancer | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Pleural Mesothelioma

United Kingdom
Neelesh Sharma MD PhD

Completed

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States

Clinical Trials on Non-Small-Cell Lung Carcinoma in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations